Patent · US Active

Lassa virus vaccine

US11464847B2 · kind B2 · utility

10Cited by

0References

18Claims

0Family size

Assignee

CureVac AG · DE

Inventors

Edith JASNY · Stuttgart, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	Dec 22, 2017
Grant date	Oct 11, 2022
Priority date	—
Expiry date	Oct 23, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections. Further, the invention relates to (pharmaceutical) compositions and vaccines comprising said mRNAs and their use for treatment or prophylaxis of a lassa virus infection. The present invention further features a kit comprising the mRNAs, (pharmaceutical) compositions or vaccines and a method for treatment or prophylaxis of lassa virus infections using said mRNAs, pharmaceutical) compositions or vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.